|Application ||WB, IHC|
|Positive Control||WB: lysate from cell line expressing V600; IHC: melanoma tissue; ELISA: 293T cells overxpressing BRAF V600|
|Application & Usage||IHC, ICC: 2 – 10 µg/mL; ELISA: 0.5 – 2 µg/mL; WB: 0.5 – 2 µg/mL.|
|Formulation||In 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide|
|Reconstitution & Storage||-20 °C|
|Precautions||Anti-BRAF V600E Rabbit Monoclonal Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Serine/threonine-protein kinase B-raf (BRAF) is a member of the Raf family. BRAF mutations are frequent in benign and malignant human tumors. BRAF V600E mutation accounts for the vast majority of BRAF alterations and the mutation induces a conformational change of the activation segment leading to a constitutive kinase activity of BRAF and consecutive phosphorylation of downstream targets. BRAF V600E mutation have been detected in melanoma, papillary thyroid carcinoma, pleomorphic xanthoastrocytomas, Langerhans cell histiocytosis, borderline ovarian cancer, ganglioglioma, colorectal carcinoma, and pilocytic astrocytoma.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.